Both rare and common genetic variants predict the onset of cardiovascular disease (CVD), but recent studies have provided compelling evidence that individuals who harbour variants that elevate their risk of CVD can substantially lower this risk by controlling lifestyle-related risk factors, such as smoking, diet, and physical activity.
This is a preview of subscription content, log in via an institution to check access.
References
Khera, A. V. et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N. Engl. J. Med. 375, 2349–2358 (2016).
Perrot, N. et al. Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: the EPIC-Norfolk prospective population study. Atherosclerosis 256, 47–52 (2017).
Thanassoulis, G. et al. Genetic associations with valvular calcification and aortic stenosis. N. Engl. J. Med. 368, 503–512 (2013).
Arsenault, B. J. et al. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Circ. Cardiovasc. Genet. 7, 304–310 (2014).
Nordestgaard, B. G. et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 31, 2844–2853 (2010).
Clarke, R. et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361, 2518–2528 (2009).
The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N. Engl. J. Med. 369, 145–154 (2013).
Pelletier-Beaumont, E. et al. Normalization of visceral adiposity is required to normalize plasma apolipoprotein B levels in response to a healthy eating/physical activity lifestyle modification program in viscerally obese men. Atherosclerosis 221, 577–582 (2012).
Zhang, H. J. et al. Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial. JAMA Intern. Med. 176, 1074–1082 (2016).
Nicholls, S. J. et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA 316, 2373–2384 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.J.A. holds a junior scholar award from the Fonds de recherche du Québec: Santé (FRQS), and has received consulting fees from Pfizer and research support from Ionis Pharmaceuticals and Pfizer. J.-P.D. is the scientific director of the International Chair on Cardiometabolic Risk, which is supported by the Foundation of Université Laval.
Supplementary information
Supplementary information S1 (figure)
Contribution of genetic and lifestyle-related risk factors to cardiovascular disease (CVD) risk. (PDF 473 kb)
Rights and permissions
About this article
Cite this article
Arsenault, B., Després, JP. Cardiovascular disease prevention: lifestyle attenuation of genetic risk. Nat Rev Cardiol 14, 187–188 (2017). https://doi.org/10.1038/nrcardio.2017.20
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2017.20
- Springer Nature Limited
This article is cited by
-
Neuroimmune axis of cardiovascular control: mechanisms and therapeutic implications
Nature Reviews Cardiology (2022)